EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische Studie

Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial

Fabio Grunspun Pitta iD, Eduardo Gomes Lima, Caio Assis Moura Tavares, Eduardo Bello Martins, Fabiana Hanna Rached, Eduardo Martelli Moreira, Bruno Mahler Mioto, Simão Augusto Lottenberg, Paula Mathias Paulino Bolta, Larissa Gonçalves Justino, Desiderio Favarato, Letícia Neves Solon Carvalho und 8 weitere

Diabetes Care · 01.06.2025 · 48 (6) · 988-995

DOI: 10.2337/dc24-2807 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 15.04.2025. Verfasst von Fabio Grunspun Pitta und 19 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do coração, Hospital das Clínicas Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Faculdade de Medic…. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Coronary Artery Bypass. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To evaluate the efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus (T2DM) undergoing elective on-pump coronary artery bypass grafting (CABG). RESEARCH DESIGN AND METHODS Investigator-initiated, pragmatic, single-center, randomized, open-label trial with blinded outcome adjudication conducted in Brazil. A total of 145 patients with T2DM scheduled for elective on-pump CABG were randomized to receive empagliflozin 25 mg daily plus standard care (n = 71) for at least 3 months, which was discontinued 72 h before surgery, or to received standard care alone (n = 74). The primary outcome was postoperative acute kidney injury (AKI) within 7 days of surgery, defined by creatinine-based criteria (namely, Acute Kidney Injury Network; Risk, Injury, Failure, Loss of Kidney Function, and End-Stage Kidney Disease; or Kidney Disease: Improving Global Outcomes). Secondary outcomes included 30-day postoperative atrial fibrillation and type 5 myocardial infarction (MI). Safety outcomes were ketoacidosis, urinary tract infection, hospital-acquired pneumonia, and wound infection within 30 days after CABG. RESULTS AKI occurred in 22.5% of the empagliflozin group vs. 39.1% in the control group (relative risk [RR] 0.57 [95% CI 0.34–0.96]; P = 0.03). Rates of atrial fibrillation (15.4% vs. 13.5%; RR 1.15 [95% CI 0.52–2.53]; P = 0.73) and type 5 MI (1.4% vs. 4.1%; RR 0.35 [95% CI 0.04–3.26]; P = 0.62) were similar between groups. No statistically significant differences between groups were observed for safety events. Three deaths occurred, all in the control group. CONCLUSIONS Empagliflozin use before on-pump CABG in patients with T2DM was associated with a reduced incidence of postoperative AKI without an increase in safety events. These findings warrant confirmation in larger clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsDiabetes Mellitus, Type 2Coronary Artery BypassHumansFemaleMaleMiddle AgedAgedAcute Kidney InjuryPostoperative Complications

Substanzen

empagliflozinGlucosidesBenzhydryl Compounds

Autor:innen und Institutionen

  • Instituto do coração, Hospital das Clínicas Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Hospital Nove de Julho, São Paulo, Brazil.
  • Serviço de endocrinologia e metabolismo, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.

ORCID-Profile: Fabio Grunspun Pitta

Zitieren

APA

Pitta, F. G., Lima, E. G., Tavares, C. A. M., Martins, E. B., Rached, F. H., Moreira, E. M., Mioto, B. M., Lottenberg, S. A., Bolta, P. M. P., Justino, L. G., Favarato, D., Carvalho, L. N. S., Pinesi, H. T., Barbosa, C. T. M., Dallan, L. A. O., Dallan, L. R. P., Barbosa, M. H. M., Kalil Filho, R., de Lemos, J. A., & Serrano, C. V. (2025). Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial. Diabetes Care, 48(6), 988-995. https://doi.org/10.2337/dc24-2807

Vancouver

Pitta FG, Lima EG, Tavares CAM, Martins EB, Rached FH, Moreira EM, et al. Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial. Diabetes Care. 2025;48(6):988-995. doi:10.2337/dc24-2807

BibTeX
@article{Pitta2025,
  author = {Pitta, Fabio Grunspun and Lima, Eduardo Gomes and Tavares, Caio Assis Moura and Martins, Eduardo Bello and Rached, Fabiana Hanna and Moreira, Eduardo Martelli and Mioto, Bruno Mahler and Lottenberg, Simão Augusto and Bolta, Paula Mathias Paulino and Justino, Larissa Gonçalves and Favarato, Desiderio and Carvalho, Letícia Neves Solon and Pinesi, Henrique Trombini and Barbosa, Camila Talita Machado and Dallan, Luís Alberto Oliveira and Dallan, Luís Roberto Palma and Barbosa, Marcelo Henrique Moreira and Kalil Filho, Roberto and de Lemos, James A and Serrano, Carlos Vicente},
  title = {Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial},
  journal = {Diabetes Care},
  year = {2025},
  volume = {48},
  number = {6},
  pages = {988--995},
  doi = {10.2337/dc24-2807}
}
Kostenlos starten →